Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6131 |
Pimasertib
AS703026,MSC1936369B,N-[(2S)-2,3-二羟基丙基]-3-[(2-氟-4-碘苯基)氨基]-4-吡啶甲酰胺,SAR 245509 |
MEK | MAPK |
Pimasertib (AS703026) 是一种高效选择性和ATP 非竞争性的MEK1/2抑制剂,可用于癌症研究。 | |||
T71240 | AS 703026 | ||
AS 703026 has been shown to inhibit LPS-induced TNFα production in macrophages/monocytes as well as protect from LPS-induced endotoxin shock. AS 703026 may be useful as an anti-inflammatory therapy for COPD patients. | |||
T71163 |
Pimasertib HCl
|
||
Pimasertib HCl is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activati... |